Bronchogen
Also known as: Peptídeo brônquico
Molecular Identifiers
Overview
Bronchial bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in bronchial tissue and supports respiratory mucosa function. Used in short cycles for protection and regeneration of the respiratory system.
Bronchogen is proposed as a bioregulator specific to bronchial tissue: the hypothesis is that the Ala-Glu-Asp-Leu tetrapeptide modulates gene expression in pneumocytes and bronchial epithelial cells, normalizing airway secretory function and supporting the integrity of the respiratory mucosa. Described use contexts include prophylaxis in chronic respiratory conditions and recovery support after pulmonary inflammation.
It has no Western regulatory approval and the evidence base is limited to publications mostly in Russian, outside the usual standards of international clinical literature. When used, it follows the pattern of Khavinson peptides: short cycles of 10-20 days, repeated 2 to 4 times per year, usually through a compounding pharmacy as off-label use.
Bronchogen is part of the family of short peptide bioregulators developed in Russia by the research group of Vladimir Khavinson from the 1970s onward, focused on tissue-specific peptides derived from animal tissues.
Within the Khavinson family, Bronchogen is most often compared to Chonluten, another short peptide aimed at the respiratory system: Bronchogen is described with a stronger focus on bronchial mucosa and airway secretory function, while Chonluten is presented as having a predominantly alveolar and immunomodulatory action. All of this comparative literature is largely Russian and preclinical.
AEDL Ala-Glu-Asp-Leu Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in bronchial tissue
- Support for respiratory mucosa integrity
- Normalization of airway secretory function
- Modulation of bronchial inflammatory response
- Bioregulatory effect on bronchopulmonary epithelium
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) |
| Frequency | 1-2 times daily, with meals |
| Timing | With meals |
| Duration | 1 month per cycle, repeat the course every 3-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Freely soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Very stable short peptide — tolerates brief temperature excursions. |
Presentations & Preparation
Vials of Bronchogen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Bronchogen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily